The purpose of this drug study is to find out whether the antibiotic lefamulin (trade name Xenleta) will cure Mycoplasma genitalium infections that have not been cured by prior antibiotics while finding out whether it is more effective if the antibiotic doxycycline is taken first.

开始日期2022-04-22

申办/合作机构

University of Washington

[+1]

NCT05225805

/ Completed临床1期

A Phase 1, Open-Label, Randomized, Crossover Study to Assess the Safety and Pharmacokinetics Following Single Doses of Oral and Intravenous Xenleta (Lefamulin) in Adult Patients With Cystic Fibrosis

This study is intended to assess the pharmacokinetic (PK) and safety of a single dose of IV and oral formulations of lefamulin in adults with cystic fibrosis (CF).

开始日期2022-03-01

申办/合作机构

Nabriva Therapeutics AG

100 项与醋酸来法莫林相关的临床结果

登录后查看更多信息

100 项与醋酸来法莫林相关的转化医学

登录后查看更多信息

100 项与醋酸来法莫林相关的专利（医药）

登录后查看更多信息

100

项与醋酸来法莫林相关的文献（医药）

2026-11-01·AMERICAN JOURNAL OF VETERINARY RESEARCH

Combining lefamulin with rifampin provides in vitro synergistic antimicrobial effects against Rhodococcus equi isolates susceptible to macrolides and rifampin

Article

作者: Wu, Jing ; Cadena, Cierra A. ; Pham, Elaine ; da Silveira, Bibiana P. ; Bordin, Angela I. ; Seeger, Marlane G. ; Cohen, Noah D. ; Alpini, Sally F. O. ; Huber, Laura ; Lawhon, Sara D.

Abstract:

Objective:

Because of lefamulin’s antimicrobial spectrum and intrapulmonary disposition, the objective of this study was to estimate MICs for macrolide- and rifampin-susceptible (MRS) and macrolide- and rifampin-resistant (MRR) isolates of Rhodococcus equi to lefamulin either alone or in combination with rifampin.

Methods:

Gradient diffusion and broth microdilution were performed to determine MICs for lefamulin alone using MRS (n = 43) and MRR isolates (61) of R equi . Twenty MRR and 20 MRS isolates were tested for synergistic effects using a checkerboard assay and the fractional inhibitory concentration index as an outcome measure.

Results:

For both MRR and MRS isolates, MIC values were significantly higher using broth microdilution (median MIC, 32 µg/mL; range, 8 to 64 µg/mL) than gradient diffusion (median MIC, 12 µg/mL; range, 5 to 28 µg/mL) testing. The fractional inhibitory concentration values of MRR isolates (median, 0.562; range, 0.250 to 1.000) were significantly higher than those of MRS isolates (median, 0.280; range, 0.039 to 1.038). In addition, the proportion of isolates exhibiting synergistic interaction was significantly greater among MRS isolates (16 of 20 [80%]) than among MRR isolates (6 of 20 [30%]).

Conclusions:

Overall, the MIC values for lefamulin against R equi were high relative to concentrations considered therapeutic in humans. When combined with rifampin, lefamulin exhibited synergistic effects for MRS but not MRR isolates.

Clinical Relevance:

Need exists for alternative antimicrobials to treat rhodococcal foal pneumonia. Results indicate that studies in foals of the pharmacokinetics and pulmonary disposition of lefamulin in combination with rifampin are warranted.

2026-10-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Streptococcus pneumoniae: Pathogenesis, virulence factors, antimicrobial resistance mechanisms, and therapeutic strategies

Review

作者: Woodard, Geoffrey E

BACKGROUND:

Streptococcus pneumoniae is a Gram-positive, facultative anaerobic bacterium and a leading cause of community-acquired pneumonia, meningitis, bacteremia, and otitis media, responsible for an estimated 1.6 million deaths annually. Despite widespread polysaccharide and conjugate vaccine programs and decades of antibiotic therapy, pneumococcal disease continues to pose major public health challenges. These challenges are increasingly understood to reflect the organism's sophisticated capacity for adaptive recombination, allowing it to exploit every selective pressure applied through vaccination and antimicrobial treatment.

OBJECTIVES:

This review aims to synthesize current understanding of pneumococcal molecular pathogenesis, virulence factor biology, vaccine evolution, antimicrobial resistance mechanisms, and novel therapeutic strategies, with explicit attention to unresolved questions and clinically consequential knowledge gaps that are inadequately addressed in existing literature.

METHODS:

A comprehensive review of the primary and review literature was conducted. The review encompassed pneumococcal colonization biology, capsule and protein virulence factor mechanisms, pilus structure and host-cell interactions, the evolutionary trajectory of conjugate vaccines from PCV7 to PCV21, global antimicrobial resistance surveillance data, and the pharmacology and clinical trial evidence for recently approved antibiotics. Particular attention was given to serotype epidemiology in low- and middle-income country (LMIC) and Indigenous populations, and to resistance dynamics driven by vaccine-era lineage shifts and antimicrobial stewardship challenges.

RESULTS:

Pneumococcal pili-particularly the RrgA adhesin of pilus islet 1-mediate binding to PECAM-1/CD31 on human brain microvascular endothelial cells, providing mechanistic insight into blood-brain barrier penetration and bacteraemic complications. Capsule expression is dynamically regulated, and the paradox of serotype 1 (thick capsule, high invasiveness, rare carriage) remains unresolved with direct implications for surveillance-guided vaccine design. Analysis of conjugate vaccine evolution reveals that PCV21's deliberate omission of serotypes 4, 6A, 9 V, and 10A creates coverage gaps for Indigenous communities where serotype 4 has re-emerged. Post-vaccine resistance dynamics are coupled to serotype replacement. Multidrug-resistant lineages expressing serotypes 15A, 15C, and 35B are expanding in the post-PCV13 era. Ceftriaxone minimum inhibitory concentration creep among phenotypically susceptible isolates presents an underappreciated clinical risk, particularly in meningitis where cerebrospinal fluid penetration is inherently limited. Azithromycin mass drug administration programs in sub-Saharan Africa generate macrolide resistance prevalences exceeding 60% in treated communities within 12-24 months, with potential for international dissemination. Of the four novel agents approved for community-acquired bacterial pneumonia-ceftaroline, lefamulin, omadacycline, and delafloxacin-none have established pharmacokinetic or clinical efficacy data supporting use in pneumococcal meningitis.

CONCLUSIONS:

S. pneumoniae functions as an integrated adaptive system rather than a pathogen with independent resistance and evasion mechanisms. Iterative vaccine reformulation is approaching diminishing returns without parallel investment in serotype-independent protein vaccines and whole-genome sequencing surveillance. The mismatch between surveillance infrastructure in high-income countries and LMIC settings, where the greatest burden is concentrated, represents a structural inequity limiting global applicability of current policies. Priority areas include expansion of genomic surveillance to LMIC settings, clinical trials with mucosal protection endpoints for protein vaccine candidates, and explicit development of therapeutics with demonstrated cerebrospinal fluid penetration against multidrug-resistant pneumococci.

2026-04-01·Journal of Comparative Effectiveness Research

Lefamulin versus omadacycline for community acquired bacterial pneumonia: a systematic review and anchored indirect treatment comparison using moxifloxacin as the common comparator.

Review

作者: Han, Sheng ; Li, Hongchao ; Wu, Meiyu

Aim: Community-acquired bacterial pneumonia (CABP) remains a major cause of morbidity and mortality worldwide, particularly among elderly and susceptible populations. Escalating antimicrobial resistance among prevalent CABP pathogens in China, combined with safety limitations of existing regimens, underscores the urgent need for novel therapeutic strategies. Lefamulin (LEF) and omadacycline (OMA), recently approved in mainland China, offer promising alternatives, but direct comparative evidence is lacking. This study aims to indirectly compare the clinical efficacy and safety outcomes of LEF versus OMA in the treatment of CABP and to explore subgroup differences in high-risk populations. Materials & methods: A systematic literature review was conducted across PubMed, Embase, the Cochrane Library and ClinicalTrials.gov from inception through March 2024, limited to English-language studies, to identify phase III randomized controlled trials evaluating LEF or OMA in adults with CABP. The Bucher method was used for the indirect comparison, with effect estimates reported as risk ratios (RRs) and 95% CIs. Similarities in trial design and populations supported the transitivity assumption. Primary end points were early clinical response (ECR), investigator-assessed clinical response (IACR) at test of cure (TOC) and treatment-emergent adverse events leading to death. Subgroup analyses were further stratified by patient age (elderly patients), presence of comorbidities and causative pathogens. Results: Three randomized controlled trials involving 2063 patients were included in this study. LEF and OMA demonstrated comparable efficacy in terms of ECR (RR: 1.01, 95% CI: 0.93-1.09) and in terms of IACR at TOC (RR: 0.95, 95% CI: 0.88-1.02). The relative risk of treatment-emergent adverse events leading to death in the LEF group compared with the OMA group was 0.67 (95% CI: 0.15-3.02), with no statistically significant difference observed. In subgroup analysis, LEF demonstrated statistically significant superiority over OMA in treating patients with Haemophilus influenzae infections (RR: 1.28, 95% CI: 1.03-1.60). No other subgroups reached statistical significance. LEF showed a numerical trend toward favoring in multiple subgroups, including the elderly, patients with comorbidities, and those infected with specific pathogens, particularly in the ECR analysis. Meanwhile, OMA demonstrated potential numerical advantages in a few subgroups defined by comorbidities or specific pathogens for IACR at TOC. Conclusions: Both LEF and OMA have been shown to be effective and safe in treating CABP. LEF demonstrated significant benefit in Haemophilus influenzae infections and consistently favorable trends in high-risk or specific infected subgroups. OMA also shows favorable trends in certain patient groups. These findings highlight the need to further accumulate additional clinical data or real-world evidence to support future comparative research. The introduction of novel antibiotics, such as LEF and OMA, represents an important step toward addressing the pressing challenge of antimicrobial resistance and improving outcomes for patients with CABP in China.

项与醋酸来法莫林相关的新闻（医药）

2026-09-17

·产业智能官

【合成生物-天然产物】近十年天然产物药物的生物合成研究进展：生物合成通路、关键酶与催化机制与基因组时代挖掘技术

《近十年天然产物药物的生物合成研究进展》全文详细总结一、论文基础信息 1.作者与单位：冯金、潘海学、唐功利（通讯）；依托中国科学院大学杭州高等研究院、中科院上海有机化学研究所生命过程小分子调控全国重点实验室。 2.期刊与发表：《合成生物学》特约评述，DOI：10.12211/2096-8280.2023-092。 3.研究时间窗口：聚焦2014.1—2023.10十年间 FDA 获批天然 / 半合成天然药物，同步梳理同期经典老药的生物合成突破性进展。 4.核心研究目的：系统分类总结各类天然药物生物合成通路、关键酶与催化机制；梳理基因组时代挖掘技术；为新药挖掘、生物制造、组合合成提供理论参考。二、绪论：天然产物药物发展脉络、优势与现存挑战（一）发展阶段变迁 1.古代应用阶段：我国《五十二病方》《神农本草经》等古籍记载数千种天然药用动植物，依靠传统提取入药。 2.经典分离时代（近代）：分离吗啡、奎宁、麻黄碱单体；青霉素开启抗生素黄金时代，大幅提升人类寿命。 3.基因组挖掘新时代（20 世纪末至今）依托基因组、转录组、生物信息学工具（BLAST、antiSMASH、MIBiG、机器学习工具 DeepBGC/metaBGC），预测超百万条生物合成基因簇（BGC）；发展基因敲除、异源表达、表观遗传激活沉默基因等挖掘手段。现状：仅 5%~15% 植物、1% 细菌、5% 真菌被系统研究，海洋微生物天然产物资源几乎未开发，巨大潜力待释放。（二）天然产物药物核心优势相较于纯化学小分子库：骨架复杂度、化学空间覆盖更广；天然进化赋予靶向微生物 / 肿瘤的独特活性，在抗感染、抗肿瘤药物中不可替代。（三）研发核心瓶颈 1.微量天然产物分离困难，重复分离已知化合物； 2.复杂天然产物化学全合成成本极高、步骤繁琐； 3.野生来源含量极低，工业化提取受限，90 年代药企缩减天然产物研发投入； 4.构效关系研究缺少大量衍生物材料。（四）技术破局方向基因组挖掘、多组学联合、微生物异源合成、体外多酶催化、AI 辅助预测等技术兴起，重新激发天然产物新药研发热潮，尤其多重耐药菌抗生素领域。三、近十年 FDA 获批天然产物药物整体统计分析 1. 总体数据 2014–2023 年 FDA 共 331 个新药分子实体，天然 / 半天然衍生物 28 个，占 8.5%，分为两大类： •纯天然产物新药（9 款，32%）：无化学修饰，直接天然来源，以动物 / 人体类固醇、微生物 / 植物聚酮、非核糖体肽为主，代表：牛磺熊去氧胆酸（TUDCA）、大麻二酚 CBD、曲贝替定。 •天然前体半合成新药（19 款，68%）：天然骨架经化学修饰优化活性 / 药代，如瑞扎芬净、青蒿琥酯、来法莫林。 2. 结构类型分布（纯天然药物细分）类固醇 18%、聚酮 7%、肽 4%、非核糖体肽 3%；半合成覆盖萜、氨基糖苷、四环素、β- 内酰胺、木脂素、生物碱等多类骨架。 3. 药物来源与适应症覆盖 •人体内源类固醇：调节激素、休克升压； •动物胆汁酸：肝病、减脂、神经退行性疾病； •植物：抗癫痫、抗疟、抗肿瘤； •陆生微生物：抗菌、抗真菌、抗炎、减肥； •海洋共生菌：抗肿瘤（曲贝替定）； •共生线虫菌：皮肤病（本维莫德 Tapinarof）。 4. 经典老药同步梳理早年获批（1941–1999）但近十年生物合成取得重大突破药物：紫杉醇、长春花碱、吗啡、秋水仙碱、东莨菪碱、奥利司他、依托泊苷、维生素 B12 等，重点解析缺失通路酶、实现微生物从头合成。四、各类天然产物药物生物合成细分进展（一）类固醇类（获批数量最多，内源 / 动物胆汁酸、激素） 1. 胆酸、去氧胆酸（2015 获批） •功能：胆酸治疗胆汁合成障碍；去氧胆酸注射溶脂改善双下巴。 •合成通路：以胆固醇为原料，肝脏 4 条合成途径（中性途径占 90%），限速酶 CYP7A1（胆固醇 7α 羟化酶）；初级胆汁酸经肠道微生物 7α- 脱羟基生成次级去氧胆酸；关键修饰酶 CYP8B1、AKR 家族、CYP27A1 等。 2. 牛磺熊去氧胆酸 TUDCA（Relyvrio，2022，渐冻症用药） •来源：黑熊肠道特有高丰度胆汁酸，人体含量极低；核心抗凋亡、抑制内质网应激。 •合成路径：体内：TCDCA 经 BSH 脱牛磺酸→CDCA；7α-HSDH/7β-HSDH 两步差向异构生成 UDCA；BAL+BAT 重新结合牛磺酸得 TUDCA；体外：双酶一步转化 TCDCA，工艺更简便。 •近十年突破：宏基因组从黑熊肠道挖掘新型 7α/7β-HSD；实现大肠杆菌、酵母异源合成；固定化双酶体系大规模体外制备；改造 7β-HSD 辅因子偏好（NADPH→廉价 NADH）降低生产成本。 3. 普拉睾酮（DHEA）、雌四醇 E4 •DHEA：肾上腺 C19 类固醇，胆固醇合成，用于绝经阴道萎缩； •雌四醇：唯一胎儿肝脏特异性雌激素，两条羟基化合成通路，新一代低风险口服避孕药原料。（二）聚酮及脂肪酸类（微生物 / 植物来源抗炎、抗癫痫、减肥药） 1. Tapinarof（本维莫德，2022 银屑病外用药，发光杆菌共生代谢物） •独特：唯一革兰氏阴性菌来源二苯乙烯，植物同类靠Ⅲ 型 PKS，细菌通路完全不同。 •合成核心：两条前体支路1）苯丙氨酸→肉桂酰 - CoA；2）亮氨酸→异戊酰 - CoA；双底物经 StlD（酮合酶）、StlC（环化酶）连续 Claisen 缩合 + Michael 加成、芳构化生成骨架；解析 StlD 晶体，发现全新 Glu154 催化三联体机制，区别传统 Cys-His-Asn。 2. 大麻二酚 CBD（Epidiolex，2018 抗癫痫） •植物合成核心两步酶：TKS（四酮合酶）+OAC（橄榄酸环化酶）协同生成橄榄酸； •分支：橄榄酸异戊烯基化生成 CBGA，CBDAS 黄素酶区域选择性环化生成 CBDA，加热脱羧得 CBD；THCAS 底物相同但质子提取位点不同，生成 THC； •合成生物学突破：Keasling 团队 2019 酵母从头合成全部大麻素；无细胞酶催化体系产量达 0.5g/L，规避种植法律限制。 3. 奥利司他（老药，减肥，利普司他汀半合成衍生物） •前体利普司他汀来自毒三素链霉菌，核心β 内酯是脂肪酶抑制活性关键； •重大突破：2014 鉴定完整 lst 操纵子；发现独特异源二聚体 KASⅢ（LstA-LstB），催化 C8、C14 脂肪酸非脱羧 Claisen 缩合（普通 FabH 为脱羧型），填补脂肪内酯合成机制空白。（三）非核糖体肽类（海洋抗肿瘤、抗真菌环肽） 1. 曲贝替定 ET-743（2015，首个海洋共生菌抗肿瘤药） •真实产菌：海鞘体内共生γ 变形杆菌Candidatus Endoecteinascidia frumentensis，而非海鞘本身； •骨架组装：3 套 NRPS（EtuA1/A2/A3），前体丝氨酸、羟乙酰单元、双分子修饰酪氨酸；多次 Pictet-Spengler 环化构建五环四氢异喹啉骨架；多步 P450 氧化、甲基转移、硫醚环修饰得到终产物；与番红霉素、萘啶霉素通路高度同源，可互相借鉴酶机制。 2. 瑞扎芬净（2023 抗真菌，棘白菌素 B 半合成） •棘白菌素 B 真菌 NRPS 六模块环脂肽，关键氨基酸 L - 高酪氨酸由 HtyABCD 酶系独立合成； •后修饰：EcdG/H/K/HtyF 多型加氧酶分步羟基化修饰环肽骨架；基因簇进化分析显示 2.9–3.9 亿年前真菌分支分化；异源改造大幅提升发酵产量。（四）木脂素类：依托泊苷（抗癌老药，鬼臼毒素半合成） •前体鬼臼毒素来自桃儿七木脂素；2015–2019 重大突破：Sattely 团队完整鉴定 10 余种通路酶（DIR、CYP450、2-ODD 双加氧酶、甲基转移酶）；在烟草异源重构，毫克级生产依托泊苷苷元，省去化学差向异构步骤，简化半合成工艺。（五）生物碱类（抗肿瘤、镇痛、抗炎经典植物药，近十年通路重大补全） 1. 长春花碱 / 长春新碱（抗癌） •双单萜吲哚生物碱二聚体；2018 发现缺失氧化还原酶 PAS/DPAS，打通 stemmadenine→长春质碱 / 水甘草碱关键步骤；2022 酵母从头合成两大单体，体外偶联得到长春花碱；毕赤酵母实现长春质碱高产（2.57mg/L）。 2. 秋水仙碱（痛风抗炎） •2020 完整解析通路：苯丙氨酸 + 酪氨酸经 Pictet-Spengler 缩合，多步甲基化，CYP71FB1 催化独特扩环生成七元环骨架；烟草异源重构前体 N - 去甲秋水仙素。 3. 吗啡 / 可待因（镇痛阿片） •关键突破：2015 发现融合酶 STORR，完成 (S)- 牛心果碱→(R)- 牛心果碱差向异构（通路卡点）；2019 鉴定 NISO 异构酶，大幅提升酵母可待因产量。 4. 东莨菪碱（抗晕动） •发现罕见Ⅲ 型聚酮合酶 PYKS 构建托品烷母核；UGT、LS 酶解决酯键合成难题；2020 酿酒酵母实现从头全合成，滴度 6mg/L。（六）萜类：来法莫林（2019 肺炎抗生素，截短侧耳素半合成） •前体截短侧耳素是真菌二萜，GGPP 经 Ple3 萜合酶 5/6/8 三环环化；Ple5/6/Ple7/Ple1 分步羟基、氧化、乙酰修饰；米曲霉异源表达产量提升 21 倍，开发大量新型抗菌衍生物。（七）肽类（人体内源）：血管紧张素Ⅱ（2017 休克升压药）肝脏血管紧张素原经肾素切为十肽 AngⅠ，ACE 酶切除末端二肽生成活性 AngⅡ，调控血管收缩与醛固酮分泌。（八）其他重要老药合成进展 1.维生素 B12：2018 大肠杆菌从头合成，发酵产量提升 250 倍；2023 构建 36 酶体外无细胞合成系统； 2.紫杉醇：红豆杉基因组解析；改造大肠杆菌 P450 实现紫杉烷前体高产；烟草叶绿体代谢工程合成 5α- 羟基紫杉二烯； 3.拓展明星天然产物：石杉碱甲、银杏内酯、普利提环肽（抗新冠潜力）的生物合成机制同步综述。五、天然产物药物研究技术革新总结 1.基因组挖掘体系：BGC 预测工具（antiSMASH、MIBiG）、宏基因组挖掘（如黑熊肠道 HSD 酶）、沉默基因激活（CRISPR、全局调控过表达）； 2.多组学联合：转录组 + 代谢组快速锁定植物缺失通路酶（秋水仙碱、依托泊苷、长春花碱）； 3.异源合成底盘：酵母、大肠杆菌、米曲霉、烟草、毕赤酵母，实现植物 / 微生物复杂天然产物从头合成； 4.体外无细胞多酶催化：大麻素、TUDCA、维生素 B12 绿色量产，不受宿主代谢调控限制； 5.蛋白工程：定向进化、理性改造改变酶底物 / 辅因子偏好（7β-HSD、StlD、CYP450）； 6.AI 与自动化平台：机器学习预测基因簇、自驱动高通量筛选，加速新型抗生素挖掘。六、现存挑战与未来发展展望（一）现存核心问题 1.大量海洋、稀有微生物、植物 BGC 功能未解析；共生菌（曲贝替定产菌）难以纯培养； 2.复杂多步通路异源表达产量低，P450 膜酶表达瓶颈； 3.多数天然产物生物合成调控网络不明，难以高效放大发酵； 4.新型天然产物筛选仍存在重复分离问题。（二）未来研究方向 1.资源挖掘重心转移：海洋微生物、极端环境菌、植物内生菌、共生微生物，开发新型抗感染（抗耐药菌）、抗肿瘤先导； 2.合成生物学制造：构建微生物细胞工厂替代野生提取，解决濒危植物（红豆杉、桃儿七）资源短缺；体外多酶体系实现绿色工业化； 3.组合生物合成创新：混搭不同来源 BGC / 酶，构建非天然天然产物，拓展构效关系，开发衍生物库； 4.技术融合：多组学 + AI + 自动化高通量筛选，建立从基因→通路→产物→活性的全流程快速筛选；CRISPR 激活沉默次级代谢基因； 5.临床转化导向：针对耐药菌、罕见病、神经退行性疾病（如 TUDCA 渐冻症）开发天然产物新药，弥补化学药物短板。七、论文整体价值 1.数据整合：首次系统汇总 2014–2023 全部 FDA 天然 / 半天然新药，按骨架分类梳理完整生物合成通路，形成领域全景综述； 2.机制汇总：系统收录近十年关键新型酶（融合酶 STORR、Ⅲ 型 PKS PYKS、异源二聚 KAS LstAB 等）独特催化机理； 3.工程化参考：大量异源合成、体外催化、蛋白改造案例，为天然产物工业化生产提供完整技术路线； 4.方向指引：明确基因组挖掘、合成生物学是天然药物研发核心突破口，为抗耐药抗生素、抗肿瘤新药开发提供理论支撑。生物智能：在生物先进产业场景中构建“状态感知-实时认知-自主决策-精准执行-学习提升”的生物科学智能（NeuroAI）；实现生物产业转型升级、DT驱动业务、价值创新创造的产业互联生态链。生物产业+物理AI=生物智能产业智能官：NeuroAI 加入知识星球“生物智能研究院”：自动化生物铸造厂OT技术（自动化+机器人+工艺+精益）和新一代IT技术（云计算+物联网+区块链+大数据+人工智能）深度融合，在场景中构建“状态感知-实时认知-自主决策-精准执行-学习提升”的生物科学智能（NeuroAI）；实现产业转型升级、DT驱动业务、价值创新创造的产业互联生态链。生物科学智能作为第四次工业革命的核心驱动力，将进一步释放历次科技革命和产业变革积蓄的巨大能量，并创造新的强大引擎；重构设计、生产、供应链和服务等经济活动各环节，形成从宏观到微观各领域的智能化新需求，催生新技术、新产品、新产业、新业态和新模式；引发经济结构重大变革，深刻改变人类生产生活方式和思维模式，实现社会生产力的整体跃升。产业智能化技术分支用来的今天，从业者必须了解如何将生物科学智能（NeuroAI）全面渗入整个公司、产品、业务等商业场景中，利用生物科学智能（NeuroAI）形成数字化、网络化和智能化力量，实现行业的重新布局、企业的重新构建和焕然新生。版权声明：产业智能官（ID：NeuroAI）发表的文章，除非确实无法确认，我们都会注明作者和来源，涉权请联系协商解决，联系、投稿邮箱：wolongzy@qq.com

2026-09-07

·动脉网

在抗菌素耐药性上升和治疗进展的背景下，社区获得性细菌性肺炎市场在预测期（2026-2036年）有望扩张 DelveInsightCommunity-Acquired Bacterial Pneumonia Market Poised for Expansion During the Forecast Period (2026-2036) Amid Rising Antimicrobial Resistance and Therapeutic Advances

The community-acquired bacterial pneumonia market is poised for continued growth, driven by the substantial global disease burden, increasing hospitalization rates, an aging population, rising prevalence of comorbidities, and the growing challenge of antimicrobial resistance. Additionally, the launch of emerging therapies such as CAL02 (Eagle Pharmaceutical/Combioxin), AON-D21 (APTARION Biotech), Trimodulin (BT588; Biotest AG), and others will further propel market growth.. 社区获得性细菌性肺炎市场有望持续增长，其驱动因素包括沉重的全球疾病负担、住院率上升、人口老龄化、合并症患病率增加以及抗菌药物耐药性带来的日益严峻的挑战。此外，CAL02（Eagle Pharmaceutical/Combioxin）、AON-D21（APTARION Biotech）、Trimodulin（BT588；Biotest AG）等新兴疗法的上市也将进一步推动市场增长。LAS VEGAS 拉斯维加斯, ，Sept. 7, 2026 2026年9月7日/PRNewswire/ -- Recently published Community-Acquired Bacterial Pneumonia Market Insights report includes a comprehensive understanding of current treatment practices, community-acquired bacterial pneumoniaemerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].. /美通社/ -- 最近发布的《社区获得性细菌性肺炎市场洞察》报告全面解析了当前的治疗实践、社区获得性细菌性肺炎新兴药物、各疗法的市场份额，以及2022年至2036年的当前市场规模和预测市场规模，并按主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）进行了细分。Community-Acquired Bacterial Pneumonia Market Summary 社区获得性细菌性肺炎市场概览The total community-acquired bacterial pneumoniatreatment market size is expected to grow positively by 2036 in the leading markets. 到2036年，主要市场的社区获得性细菌性肺炎治疗市场总规模预计将实现正增长。The United States accounted for the largest community-acquired bacterial pneumoniatreatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 2025年，在七大主要市场（7MM）中，美国占据了最大的社区获得性细菌性肺炎治疗市场规模，其他主要市场包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本。Around 周围80% 80%of the nearly 在将近4 million 400万cases of community-acquired pneumonia (CAP) in the US are classified as CABP. This high prevalence of CABP within the broader category of CAP underscores the significant burden of bacterial pathogens in pneumonia cases. 美国的社区获得性肺炎（CAP）病例被归类为社区获得性细菌性肺炎（CABP）。在更广泛的CAP类别中，CABP的高患病率突显了细菌病原体在肺炎病例中的重大负担。Leading community-acquired bacterial pneumonia companies, such as 社区获得性细菌性肺炎领域的领先企业，例如Eagle Pharmaceutical, Combioxin, APTARION Biotech, Biotest AG, 鹰牌制药公司，Combioxin公司，APTARION生物技术公司，Biotest股份公司，and others, are developing new community-acquired bacterial pneumonia treatmentdrugs that can be available in the community-acquired bacterial pneumonia market in the coming years. 以及其他公司正在开发新的社区获得性细菌性肺炎治疗药物，这些药物有望在未来几年内上市。The promising community-acquired bacterial pneumonia therapiesin clinical trials include 临床试验中前景广阔的社区获得性细菌肺炎疗法包括CAL02, AON-D21, Trimodulin (BT588), CAL02，AON-D21，Trimodulin（BT588），and others. 以及其他。Discover CABP clinical trial 2026 update press release @ 发现2026年社区获得性细菌性肺炎（CABP）临床试验更新的新闻稿 @https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-marketKey Factors Driving the Growth of the Community-Acquired Bacterial Pneumonia Market 推动社区获得性细菌性肺炎市场增长的关键因素Rising Burden of Community-Acquired Bacterial Pneumonia: 社区获得性细菌性肺炎的负担日益加重：The persistent incidence of community-acquired bacterial pneumonia (CABP), particularly among older adults, children, and individuals with underlying conditions, is driving demand for effective treatment options. The associated morbidity, hospitalization rates, and mortality further support market growth.. 社区获得性细菌性肺炎（CABP）的持续发病率，尤其是在老年人、儿童和患有基础疾病的人群中，正在推动对有效治疗方案的需求。相关的发病率、住院率和死亡率进一步促进了市场增长。Increasing Antimicrobial Resistance: 日益严重的抗菌药物耐药性：The growing prevalence of antibiotic-resistant bacterial pathogens is creating a need for novel antibiotics and therapies with improved efficacy against resistant strains. This is encouraging pharmaceutical companies to invest in the development of next-generation antibacterial treatments. 抗生素耐药性细菌病原体的日益普遍，使得人们迫切需要开发对耐药菌株具有更好疗效的新型抗生素和疗法。这正促使制药公司加大对下一代抗菌治疗药物研发的投入。Advancements in Antibiotic Development: 抗生素研发的进展：Ongoing research into novel antibacterial mechanisms, improved formulations, and targeted therapies is expanding the treatment landscape for CABP. The emergence of differentiated therapies may provide additional options for patients who have limited responses to conventional antibiotics. 针对新型抗菌机制、改良制剂和靶向疗法的持续研究正在拓展社区获得性细菌性肺炎（CABP）的治疗格局。差异化疗法的涌现可能为对传统抗生素反应有限的患者提供额外的治疗选择。Launch of CABP Drugs: 社区获得性细菌性肺炎（CABP）药物上市：The dynamics of the CABP market are expected to change in the coming years due to the launch of emerging therapies such as 由于新兴疗法的推出，预计未来几年CABP市场的动态将发生变化，例如CAL02 CAL02(Eagle Pharmaceutical/Combioxin), （伊格尔制药/Combioxin）AON-D21 AON-D21(APTARION Biotech), （APTARION Biotech），Trimodulin 曲莫杜林(BT588; Biotest AG), and others. (BT588；Biotest AG) 等。Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that emerging candidates such as CAL02 and AON-D21 are being developed to complement conventional antibiotic treatment by targeting bacterial toxins, virulence factors, and host inflammatory responses. These novel approaches aim to improve clinical outcomes in severe CABP and address challenges associated with antimicrobial resistance and treatment failure.. DelveInsight 预测与分析项目经理 Aparna Thakur 表示，CAL02 和 AON-D21 等新兴候选药物正在开发中，旨在通过靶向细菌毒素、毒力因子和宿主炎症反应，作为传统抗生素治疗的补充。这些新颖疗法旨在改善严重社区获得性细菌性肺炎（CABP）患者的临床结局，并应对与抗菌素耐药性和治疗失败相关的挑战。Community-Acquired Bacterial Pneumonia Market Analysis 社区获得性细菌性肺炎市场分析Community-acquired pneumonia continues to represent a substantial global health burden, contributing significantly to both morbidity and mortality. Identifying the optimal antibiotic therapy for CAP, however, remains challenging because of several clinical and epidemiological considerations. 社区获得性肺炎（CAP）仍然构成重大的全球健康负担，显著导致发病率和死亡率。然而，由于多种临床和流行病学因素，确定CAP的最佳抗生素治疗方案仍具挑战性。The treatment landscape is also evolving as the efficacy and safety profiles of established antibiotics change over time. The growing prevalence of antimicrobial resistance has further complicated treatment decisions by reducing the effectiveness of previously reliable therapies against certain pathogens.. 随着既定抗生素的疗效和安全性特征随时间发生变化，治疗格局也在不断演变。抗菌药物耐药性的日益普遍进一步复杂化了治疗决策，因为它降低了以往对某些病原体可靠疗法的有效性。As a result, clinicians must carefully select antibiotic regimens based on local resistance trends, suspected causative pathogens, disease severity, and individual patient characteristics. 因此，临床医生必须根据当地的耐药趋势、疑似致病菌、疾病严重程度以及患者个体特征，谨慎选择抗生素治疗方案。The introduction of newer antibiotics has expanded the therapeutic options available for CAP in recent years. 近年来，新型抗生素的问世扩大了社区获得性肺炎（CAP）的治疗选择。Agents such as 诸如以下代理：omadacycline (NUZYRA), delafloxacin (BAXDELA), and lefamulin (XENLETA) 奥马环素（NUZYRA）、德拉沙星（BAXDELA）和来法莫林（XENLETA）have strengthened the CAP treatment armamentarium, particularly for patients who are unsuitable for or do not adequately respond to conventional therapies. 增强了社区获得性肺炎（CAP）的治疗手段，尤其适用于不适合或对传统疗法反应不足的患者。With broader antimicrobial coverage and, in some cases, novel mechanisms of action, these therapies provide additional options for managing infections caused by a diverse range of CAP pathogens. 凭借更广泛的抗菌谱以及在某些情况下的新颖作用机制，这些疗法为管理由多种社区获得性肺炎（CAP）病原体引起的感染提供了更多选择。Several antibiotics are also approved for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), including 多种抗生素也已获批用于治疗医院获得性细菌性肺炎（HABP）和呼吸机相关性细菌性肺炎（VABP），包括cefiderocol (FETROJA), ceftazidime-avibactam (AVYCAZ), telavancin (VIBATIV) 头孢地罗（FETROJA）、头孢他啶-阿维巴坦（AVYCAZ）、特拉万星（VIBATIV）, and the combination of ，以及……的组合ceftolozane and tazobactam (ZERBAXA) 头孢洛扎和他唑巴坦（ZERBAXA）, among others. ，等等。By comparison, the pipeline for emerging therapies specifically targeting CAP remains relatively limited, although ongoing research and clinical development programs are focused on addressing unmet treatment needs. 相比之下，专门针对社区获得性肺炎（CAP）的新兴疗法研发管线仍然相对有限，尽管当前的研究和临床开发项目正致力于满足尚未被满足的治疗需求。The emerging community-acquired bacterial pneumonia (CABP) pipeline includes candidates such as 新兴的社区获得性细菌性肺炎（CABP）研发管线包括以下候选药物：CAL02 CAL02, developed by Eagle Pharmaceuticals and Combioxin SA, and 由Eagle Pharmaceuticals和Combioxin SA开发，并且AON-D21 AON-D21from APTARION Biotech, among others. 来自APTARION Biotech等公司。These investigational therapies employ innovative approaches aimed at overcoming antimicrobial resistance and improving clinical outcomes, particularly among patients with severe CABP. 这些在研疗法采用创新方法，旨在克服抗菌药物耐药性并改善临床结局，尤其是在患有严重社区获得性细菌性肺炎（CABP）的患者中。Overall, the availability of both established and recently approved antibiotics has broadened the treatment landscape for CAP, including cases associated with complications or resistance concerns. 总体而言，既有抗生素和近期获批抗生素的可及性拓宽了社区获得性肺炎（CAP）的治疗格局，包括与并发症或耐药性问题相关的病例。Commonly used antimicrobial regimens include macrolides, either alone or in combination with β-lactams; amoxicillin as monotherapy or combined with a macrolide; fluoroquinolones; and third-generation cephalosporins administered in combination with a macrolide. 常用的抗菌方案包括：大环内酯类（单用或与β-内酰胺类联用）、阿莫西林（单用或与大环内酯类联用）、氟喹诺酮类，以及第三代头孢菌素联合大环内酯类。Community-Acquired Bacterial Pneumonia Competitive Landscape 社区获得性细菌肺炎竞争格局Some of the CABP drugs under development include 正在研发中的社区获得性细菌性肺炎（CABP）药物包括CAL02 CAL02(Eagle Pharmaceutical/Combioxin), （Eagle Pharmaceutical/Combioxin）AON-D21 AON-D21(APTARION Biotech), （APTARION Biotech）Trimodulin 曲莫杜林(BT588; Biotest AG), and others. （BT588；Biotest AG）等。Eagle Pharmaceutical/Combioxin's CAL02 Eagle Pharmaceutical/Combioxin 的 CAL02is a Phase II-stage therapeutic candidate being developed to address severe infections, particularly community-acquired pneumonia (CAP) among critically ill ICU patients. The treatment consists of liposomes formulated with cholesterol and sphingomyelin, with sphingomyelin incorporated for its distinctive anti-infective properties. 是一种处于II期临床阶段的候选治疗药物，旨在治疗严重感染，特别是重症监护室（ICU）危重患者中的社区获得性肺炎（CAP）。该疗法由含有胆固醇和鞘磷脂的脂质体组成，其中掺入鞘磷脂是利用其独特的抗感染特性。This formulation highlights the therapeutic potential of antimicrobial lipids in combating bacterial infections.. 该制剂突显了抗菌脂质在对抗细菌感染方面的治疗潜力。CAL02 works by neutralizing bacterial virulence effectors, which play a significant role in the development of organ dysfunction and life-threatening complications associated with severe infections. By targeting these virulence mechanisms rather than solely focusing on bacterial eradication, CAL02 aims to limit disease progression and potentially improve clinical outcomes.. CAL02 通过中和细菌毒力效应因子发挥作用，这些效应因子在严重感染相关的器官功能障碍和危及生命的并发症的发展中起着重要作用。CAL02 旨在通过靶向这些毒力机制，而非仅仅专注于清除细菌，来限制疾病进展并可能改善临床结局。The candidate has received 候选人已收到Fast Track and Qualified Infectious Disease Product (QIDP) designations 快速通道认定和合格传染病产品（QIDP）认定from the U.S. FDA. These regulatory designations can provide an additional five years of market exclusivity, potentially extending the total exclusivity period to eight or ten years. 来自美国食品药品监督管理局（FDA）。这些监管认定可提供额外的五年市场独占期，可能将总独占期延长至八年或十年。APTARION Biotech's AON-D21 阿普塔里昂生物科技公司的AON-D21is another therapeutic candidate currently undergoing Phase II clinical development. It is a PEGylated, L-configured aptamer, a synthetic molecule engineered to selectively bind to specific biological targets. AON-D21 is designed to modulate the complement pathway by selectively binding to and neutralizing C5a, a key component of the immune system.. 是另一种目前正在接受II期临床开发的治疗候选药物。它是一种聚乙二醇化、L构型的适配体，这是一种经过工程改造以选择性结合特定生物靶点的合成分子。AON-D21旨在通过选择性结合并中和免疫系统的关键组分C5a来调节补体通路。C5a serves as an important mediator of immune activity and plays a central role in coordinating inflammatory responses. Its broad involvement in immune regulation creates opportunities for C5a-targeted therapies across multiple disease areas, particularly conditions in which excessive or dysregulated immune responses contribute to disease progression.. C5a是免疫活动的重要介质，在协调炎症反应中发挥核心作用。其广泛参与免疫调节，为针对C5a的疗法在多种疾病领域的应用创造了机会，尤其是在那些由过度或失调的免疫反应导致疾病进展的病症中。The anticipated launch of these emerging therapies are poised to transform the CABPmarket landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CABPmarket landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期上市将在未来几年内改变社区获得性细菌性肺炎（CABP）市场的格局。随着这些前沿疗法不断成熟并获得监管批准，预计将重塑 CABP 市场格局，提供新的护理标准，并为医疗创新和经济增长带来机遇。Discover more about the latest treatments for CABP 2026 @ 探索2026年社区获得性细菌性肺炎（CABP）的最新治疗方案 @Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials 社区获得性细菌肺炎治疗药物临床试验Community-Acquired Bacterial Pneumonia Epidemiology Segmentation 社区获得性细菌性肺炎的流行病学细分The CABPepidemiology section provides insights into the historical and current CABPpatient pool and forecasted trends for the leading markets. In the US, mild cases of CABP constituted the highest proportion, approximately CABP流行病学部分提供了对历史和当前CABP患者群体以及主要市场预测趋势的见解。在美国，轻度CABP病例占比最高，约为50% 百分之五十of total incident cases, followed by moderate cases at around 占总病例数的，其次是中等病例，约占35% 百分之三十五. 。The CABPtreatment market reportproffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: 《社区获得性细菌性肺炎（CABP）治疗市场报告》提供了2022–2036年研究期间主要市场的流行病学分析，细分如下：Total Incident Cases of CABP 社区获得性细菌性肺炎（CABP）总病例数Gender-specific Cases of CABP 社区获得性细菌性肺炎的性别特异性病例Severity-specific Cases of CABP 按严重程度分类的社区获得性细菌性肺炎病例Pathogen-specific Cases of CABP 社区获得性细菌性肺炎（CABP）的病原体特异性病例Age-specific Cases of CABP 按年龄分组的社区获得性细菌性肺炎病例Total Treated Cases of CABP 社区获得性肺炎（CABP）总治疗病例数Community-Acquired Bacterial Pneumonia Market Report Metrics 社区获得性细菌性肺炎市场报告指标Details 详情Study Period 学习阶段2022–2036 2022–2036Coverage 覆盖范围7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 700万 [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。Community-Acquired Bacterial Pneumonia Epidemiology Segmentation 社区获得性细菌性肺炎流行病学细分Total Incident Cases of CABP, Gender-specific Cases of CABP, Severity-specific Cases of CABP, Pathogens-specific Cases of CABP, Age-specific Cases of CABP, and Total Treated Cases of CABP 社区获得性细菌性肺炎（CABP）的总病例数、按性别划分的CABP病例数、按严重程度划分的CABP病例数、按病原体划分的CABP病例数、按年龄划分的CABP病例数，以及CABP的总治疗病例数Key Community-Acquired Bacterial Pneumonia Companies 社区获得性细菌性肺炎领域的主要企业Eagle Pharmaceutical, Combioxin, APTARION Biotech, Biotest AG, Nabriva Therapeutics, Paratek Pharmaceutical, and others 鹰制药公司、Combioxin公司、APTARION生物技术公司、Biotest股份公司、Nabriva治疗公司、Paratek制药公司及其他公司KeyCommunity-Acquired Bacterial PneumoniaTherapies 社区获得性细菌性肺炎的主要疗法CAL02, AON-D21, Trimodulin (BT588), XENLETA, NUZYRA, and others CAL02、AON-D21、Trimodulin（BT588）、XENLETA、NUZYRA 等Scope of the 范围Community-Acquired Bacterial Pneumonia 社区获得性细菌性肺炎Market Report 市场报告Community-Acquired Bacterial Pneumonia Patient Population Forecast 社区获得性细菌性肺炎患者人群预测Community-Acquired Bacterial Pneumonia Therapeutics Market Size 社区获得性细菌肺炎治疗药物市场规模Community-Acquired Bacterial Pneumonia Pipeline Analysis 社区获得性细菌性肺炎研发管线分析Community-Acquired Bacterial Pneumonia Market Size and Trends 社区获得性细菌性肺炎市场规模与趋势Community-Acquired Bacterial Pneumonia Market Opportunity 社区获得性细菌性肺炎市场机遇Community-Acquired Bacterial Pneumonia Market Unmet Needs 社区获得性细菌肺炎市场的未满足需求KOL's Views on Community-Acquired Bacterial Pneumonia 关键意见领袖对社区获得性细菌性肺炎的观点Community-Acquired Bacterial Pneumonia Market Access and Reimbursement 社区获得性细菌性肺炎的市场准入与报销Download the report to understand the CABP treatment market@ 下载报告以了解社区获得性细菌性肺炎（CABP）治疗市场Community-Acquired Bacterial Pneumonia Drugs 社区获得性细菌性肺炎药物Table of Contents 目录1 1Community-Acquired Bacterial Pneumonia Market Key Insights 社区获得性细菌性肺炎市场关键洞察2 2Community-Acquired Bacterial Pneumonia Market Report Introduction 社区获得性细菌性肺炎市场报告简介3 3Executive Summary 执行摘要4 4Key Events 关键事件5 5Epidemiology and Market Methodology 流行病学与市场方法论6 6Community-Acquired Bacterial Pneumonia (CABP) Market Overview at a Glance 社区获得性细菌性肺炎（CABP）市场概览6.1 6.1Clinical Landscape Analysis (By Phase, Molecule Type, and RoA) 临床格局分析（按阶段、分子类型和作用机制）6.2 6.2Market Share (%) Distribution of CABP by Therapies in the 7MM, in 2025 2025年七个主要市场（7MM）中按疗法划分的社区获得性细菌性肺炎（CABP）市场份额（%）分布6.3 6.3Market Share (%) Distribution of CABP by Therapies in the 7MM, in 2036 2036年七个主要国家（7MM）社区获得性细菌性肺炎（CABP）按治疗方案划分的市场份额（%）分布7 7Disease Background and Overview 疾病背景与概述7.1 7.1Introduction 引言7.2 7.2Etiology 病因学7.3 7.3Pathophysiology 病理生理学7.4 7.4Signs and Symptoms of CABP 社区获得性细菌性肺炎的体征和症状7.5 7.5Clinical Characteristics 临床特征7.6 7.6Immunology & Risk Factors 免疫学与风险因素7.7 7.7Diagnosis 诊断7.8 7.8Prognosis 预后7.9 7.9Diagnostic Biomarkers for CABP 社区获得性细菌性肺炎（CABP）的诊断生物标志物8 8Treatment and Management 治疗与管理8.1 8.1Antibiotic therapy 抗生素治疗8.2 8.2Diuretics 利尿剂8.3 8.3Corticosteroids 皮质类固醇8.4 8.4Later management 后期管理8.5 8.5Diagnostic and Treatment Guidelines 诊断与治疗指南9 9Epidemiology and Patient Population 流行病学与患者人群9.1 9.1Key Findings 主要发现9.2 9.2Assumptions and Rationale 假设与理由9.3 9.3Total Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM 七大主要市场（7MM）中社区获得性细菌性肺炎（CABP）的总发病病例数9.4 9.4The United States 美国9.5.1 9.5.1Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）的发病病例9.5.2 9.5.2Gender-specific Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）的性别特异性病例9.5.3 9.5.3Severity-specific Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）的严重程度特异性病例9.5.4 9.5.4Pathogen-specific Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）的病原体特异性病例9.5.5 9.5.5Age-specific Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）的年龄别病例数9.5.6 9.5.6Total treated Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）治疗病例总数9.6 9.6EU4 and the UK 欧盟四国与英国9.7 9.7Japan 日本10 10Patient Journey 患者旅程11 十一Marketed CABP Therapies 已上市的社区获得性细菌性肺炎（CABP）治疗药物11.1 11.1Marketed Competitive Landscape 市场竞争格局11.2 11.2Lefamulin (XENLETA): Nabriva Therapeutics lefamulin（XENLETA）：Nabriva Therapeutics11.2.1 11.2.1Drug Description 药物说明11.2.2 11.2.2Regulatory Milestones 监管里程碑11.2.3 11.2.3Other Developmental Activities 其他发展性活动11.2.4 11.2.4Summary of Pivotal Trials 关键试验总结11.2.5 11.2.5Clinical Development 临床开发11.2.5.1 11.2.5.1Clinical Trial Information 临床试验信息11.2.6 11.2.6Safety and Efficacy 安全性与有效性11.2.7 11.2.7Analyst's Views 分析师观点11.3 11.3Omadacycline (NUZYRA): Paratek Pharmaceuticals 奥马环素（NUZYRA）：Paratek PharmaceuticalsList will be continued in the report… 列表将在报告中继续……12 十二Emerging CABP Drugs 新兴的社区获得性细菌性肺炎（CABP）药物12.1 12.1Emerging Competitive Landscape 新兴竞争格局12.2 12.2CAL02: Eagle Pharmaceutical/Combioxin SA CAL02：伊格尔制药/Combioxin SA12.2.1 12.2.1Drug Description 药物说明12.2.2 12.2.2Other Developmental Activities 其他发展性活动12.2.3 12.2.3Clinical Development 临床开发12.2.3.1 12.2.3.1Clinical Trials Information 临床试验信息12.2.4 12.2.4Safety and Efficacy 安全性与有效性12.2.5 12.2.5Analyst's Views 分析师观点12.3 12.3AON-D21 (anti-C5a): APTARION Biotech AG AON-D21（抗C5a）：APTARION Biotech AGList will be continued in the report… 列表将在报告中继续……13 13Other Therapies: Generics 其他疗法：仿制药13.1 13.1Amoxicillin 阿莫西林13.2 13.2Azithromycin 阿奇霉素13.3 13.3Clarithromycin 克拉霉素13.4 13.4Doxycycline 多西环素13.5 13.5Moxifloxacin 莫西沙星13.6 13.6Vaccine 疫苗14 14Community-Acquired Bacterial Pneumonia Market: 7MM Analysis 社区获得性细菌性肺炎市场：七国市场分析14.1 14.1Key Findings 主要发现14.2 14.2Community-Acquired Bacterial Pneumonia Market Outlook 社区获得性细菌性肺炎市场前景14.3 14.3Conjoint analysis 联合分析14.4 14.4Key Community-Acquired Bacterial Pneumonia Market Forecast Assumptions 社区获得性细菌性肺炎市场预测的关键假设14.5 14.5Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the 7 MM 七大主要市场社区获得性细菌性肺炎（CABP）的总体市场规模14.6 14.6Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies In 7MM 七大主要市场（7MM）中社区获得性细菌性肺炎（CABP）按疗法划分的市场规模14.7 14.7The United States CABP Market Size 美国社区获得性细菌性肺炎（CABP）市场规模14.7.1 14.7.1Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the United States 美国社区获得性细菌性肺炎（CABP）的总体市场规模14.7.2 14.7.2Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the United States 美国社区获得性细菌性肺炎（CABP）按疗法划分的市场规模14.8 14.8EU4 and the UK CABP Market 欧盟4国及英国CABP市场14.9 14.9Japan CABP Market Size 日本社区获得性细菌性肺炎（CABP）市场规模15 十五KOL Views KOL观点16 十六Unmet Needs 未满足的需求17 17SWOT Analysis SWOT分析18 十八CABP Market Access and Reimbursement 社区获得性细菌性肺炎（CABP）的市场准入与报销19 十九Bibliography 参考文献20 二十Community-Acquired Bacterial Pneumonia Market Report Methodology 社区获得性细菌性肺炎市场报告方法论Related Reports 相关报告Community-Acquired Bacterial Pneumonia Clinical Trial Analysis 社区获得性细菌性肺炎临床试验分析Community-Acquired Bacterial Pneumonia Pipeline – 2026 社区获得性细菌性肺炎研发管线 – 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the keyCABP companies, including 报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键社区获得性细菌性肺炎（CABP）企业的全面洞察，包括Mesoblast, Taiwan Liposome Company, Biosplice, Centrexion Therapeutics, Latigo Biotherapeutics, Pacira BioSciences, Contineum Therapeutics, Tris Pharma, Flexion, Taisho Pharmaceutical, Bioventus, Mesoblast、台湾脂质体公司、Biosplice、Centrexion Therapeutics、Latigo Biotherapeutics、Pacira BioSciences、Contineum Therapeutics、Tris Pharma、Flexion、大正制药、Bioventus，and others. 以及其他。Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market 医院获得性和呼吸机相关性细菌性肺炎市场Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia 医院获得性及呼吸机相关性细菌性肺炎Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– 2036 – 2036report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and keyHABP/VABP companies, including 报告提供对疾病的深入理解、历史及预测流行病学，以及市场趋势、市场驱动因素、市场障碍和关键HABP/VABP公司，包括Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aerucin, Motif Bio, 巴塞尔大学、默克、盐野义、辉瑞、Aridis Pharmaceuticals、Polyphor、Aerucin、Motif Bio，and others. 以及其他。Pneumonia Market 肺炎市场Pneumonia Market Insights, Epidemiology, and Market Forecast – 2036 肺炎市场洞察、流行病学及市场预测 – 2036report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pneumonia companies including 报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和包括在内的关键肺炎企业Aridis Pharmaceuticals, Aptarion Biotech, Biotest AG, Vaxcyte, Inc., CanSinoBIO, Inventprise, BioVersys, Aridis Pharmaceuticals，Aptarion Biotech，Biotest AG，Vaxcyte, Inc.，康希诺生物，Inventprise，BioVersys，and others. 以及其他。Bacterial Pneumonia 细菌性肺炎Market 市场Bacterial Pneumonia 细菌性肺炎Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2036 2036report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bacterial pneumoniacompanies including 本报告深入剖析了疾病概况、历史及预测流行病学数据，以及市场趋势、市场驱动因素、市场壁垒和细菌性肺炎领域的主要企业，包括Pfizer, Forecast Laboratories, Melinta Therapeutics Inc., Merck Sharp & Dohme LLC, Melinta Therapeutics Inc., Evopoint Biosciences Inc., Paratek Pharmaceuticals Inc., Wockhardt, Clarametyx Biosciences Inc., AstraZeneca, Cumberland Pharmaceuticals, Eagle Pharmaceuticals Inc., Bayer 辉瑞公司、Forecast Laboratories、Melinta Therapeutics Inc.、默沙东有限责任公司、Melinta Therapeutics Inc.、Evopoint Biosciences Inc.、Paratek Pharmaceuticals Inc.、Wockhardt、Clarametyx Biosciences Inc.、阿斯利康、Cumberland Pharmaceuticals、Eagle Pharmaceuticals Inc.、拜耳, ，and others. 以及其他。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来帮助制药公司提升绩效。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [emailprotected]+14699457679 +14699457679www.delveinsight.com www.delveinsight.comSOURCE DelveInsight Business Research, LLP 来源：DelveInsight Business Research, LLP21 二十一% 百分之more press release views with 更多新闻稿浏览量，借助Request a Demo 申请演示

2026-08-28

·中国基金报

健友股份上半年实现营收19.26亿元，经营现金流同比增长78.82%

中国基金报记者赵新亮8月27日晚，健友股份（603707.SH）发布2026年半年度报告。报告期内，公司实现营业收入19.26亿元，同比下降2.71%；归属于上市公司股东的净利润1.88亿元，同比下降34.48%；经营活动产生的现金流量净额7.34亿元，同比增长78.82%，主要系报告期销售回款增加。对于利润端回落，公司在报告中表示，主要系报告期内制剂销量提升，原材料、生产制造等营业成本同步增加；同时公司加大新产品市场布局，新品推广、市场宣传力度加大导致相关销售费用增长。2026年上半年，公司研发投入占营业收入的比重为14.59%，维持较高投入强度。报告期内，公司资源继续向高毛利注射剂、生物类似药倾斜，推进从原料药厂商向国际化高端注射剂企业的战略转型。截至目前，转型成果已初步显现。据半年报，公司上半年制剂业务收入实现规模增长，占总营收比重持续提升；原料药业务方面，受行业周期底部、原料价格低位运行影响，公司主动优化产销节奏、控制低效产能投放，收入占比持续收缩。产品获批方面，报告期内，公司亚硒酸注射液获得美国FDA批准，来法莫林注射液获得美国FDA生产场地转移批准，美国市场产品矩阵持续扩充。7月，公司门冬胰岛素获得美国FDA批准，甘精胰岛素、赖脯胰岛素继续推进FDA申报。此前，健友股份引入的阿达木单抗生物类似药Yusimry 已在美国上市，公司成为首家持有该品种美国完整批件的中国企业。2025 年4 月，利拉鲁肽注射液获FDA 批准，系国内企业进军美国GLP‑1 市场的少数案例。与双成药业合作的注射用紫杉醇（白蛋白结合型）由美国子公司Meitheal 负责商业化。叠加新近获批的门冬胰岛素及正在推进注册的甘精、赖脯胰岛素，公司美国市场生物药与高端注射剂产品梯队已初步成型。上半年，健友股份创新药管线亦稳步推进。公司XTMAB-16肺结节病单抗上半年持续推进III期临床，该品种拥有FDA孤儿药资格，目前全球范围内无同类已上市特效药。此外，公司自复制mRNA肿瘤免疫创新药已完成候选分子筛选，并搭建完整LNP递送工艺平台，配套多项自主发明专利。报告显示，健友股份当前400 余人研发团队稳定扩充，在南京、成都、北美设有三大研发中心，分别承担mRNA核酸创新药、单抗早期开发、生物药临床与全球药监沟通职能。同时持续完善多肽固相合成、复杂脂质体缓控释注射剂、工艺转化三大核心技术平台，以期进一步提升研发转化效率。商业化全球布局方面，公司现有近百款注射剂产品在美国商业化销售，覆盖美国临床主流刚需注射剂品种，并依托Meitheal本土渠道直接对接GPO、大型药品分销商及连锁药房。2026年上半年公司加大欧洲市场投入，同步推进多款注射剂跨国注册申报，打造美国之外第二大海外核心市场；并以新加坡子公司为运营枢纽，开拓东南亚、中东、南美、北非等新兴市场。健友股份表示，未来将持续落实“原料药打底、高端制剂为主体、生物药创新为未来核心增长极”的长期战略，稳步推进全球多市场商业化布局，现有12条FDA无菌产线可充分支撑未来三年新品商业化放量；CDMO业务将持续拓展北美临床样品生产与海外商业化订单，进一步扩大服务业务盈利空间。

100 项与醋酸来法莫林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11632	醋酸来法莫林	J01XX12	DB12825

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
社区获得性肺炎	加拿大	Sunovion Pharmaceuticals Canada, Inc.	2020-07-10
流感病毒感染	加拿大	Sunovion Pharmaceuticals Canada, Inc.	2020-07-10
社区获得性细菌性肺炎	美国	Hong Kong King-Friend Industrial Co. Ltd.	2019-08-19

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
生殖器支原体感染	临床2期	美国	Nabriva Therapeutics Plc	2022-04-22
细菌感染	临床2期	美国	Nabriva Therapeutics AG	2010-05-01
皮肤和皮肤结构感染	临床2期	美国	Nabriva Therapeutics AG	2010-05-01
囊性纤维化	临床1期	美国	Nabriva Therapeutics AG	2022-03-01
医院获得性肺炎	临床前	爱尔兰	Nabriva Therapeutics Plc	2022-01-30
骨髓炎	临床前	爱尔兰	Nabriva Therapeutics Plc	2022-01-30
假体关节感染	临床前	爱尔兰	Nabriva Therapeutics Plc	2022-01-30
性传播疾病	临床前	爱尔兰	Nabriva Therapeutics Plc	2022-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05111002 (CTgov)	临床1/2期	生殖器支原体感染	12	Lefamulin (Lefamulin Alone)	遞選鏇衊範衊艱襯繭窪 = 淵選簾製範餘憲範淵廠觸範壓遞憲憲鏇顧鏇糧 (願窪窪齋膚網鹹衊壓夢, 糧壓積鹽選鬱淵遞構壓 ~ 繭鹽鹹範獵願醖構艱廠) 更多	-	2024-10-16
				Doxycycline+Lefamulin (Doxycycline Followed by Lefamulin)	遞選鏇衊範衊艱襯繭窪 = 襯蓋齋鹹築齋鑰願選夢觸範壓遞憲憲鏇顧鏇糧 (願窪窪齋膚網鹹衊壓夢, 繭遞窪遞壓艱築積廠積 ~ 選築糧襯襯獵積鬱鑰窪) 更多
NCT05225805 (CTgov)	临床1期	囊性纤维化	13	Lefamulin (Lefamulin Oral Treatment)	繭壓憲積獵艱艱鏇膚齋(積餘襯網選窪築壓鏇鏇) = 願憲淵憲鹽鹽顧餘壓壓鬱醖簾遞憲遞鑰網願餘 (簾積鏇鏇膚壓衊願獵範, 遞淵積製齋餘憲壓襯衊 ~ 築淵觸壓壓餘窪鏇憲積) 更多	-	2024-06-17
				Lefamulin IV (Lefamulin IV Treatment)	繭壓憲積獵艱艱鏇膚齋(積餘襯網選窪築壓鏇鏇) = 醖築鹽繭築鏇衊簾鹹窪鬱醖簾遞憲遞鑰網願餘 (簾積鏇鏇膚壓衊願獵範, 鏇齋艱鑰鹽製鏇淵選鹽 ~ 廠顧選鹽膚獵廠願憲衊) 更多
NCT02559310 \| NCT02813694 (LEAP 1/2, Pubmed \| BMC Pulm Med)	临床3期	社区获得性细菌性肺炎	-	Lefamulin	齋膚鹽積醖廠構夢製衊(齋遞淵鑰遞膚窪壓顧鬱) = 餘憲齋顧獵願淵餘鹽壓網鹽艱簾糧膚鹽餘夢夢 (願鏇衊遞蓋製壓簾範願 )	积极	2021-05-08
				Moxifloxacin	齋膚鹽積醖廠構夢製衊(齋遞淵鑰遞膚窪壓顧鬱) = 餘製衊醖鬱廠憲壓獵選網鹽艱簾糧膚鹽餘夢夢 (願鏇衊遞蓋製壓簾範願 )
NCT01119105 (CTgov)	临床2期	细菌感染 \| 皮肤和皮肤结构感染	210	BC-3781 (BC-3781 Dose 100mg)	觸糧窪壓選顧廠憲憲憲 = 鏇憲蓋獵範鏇齋夢餘範鹹遞淵網艱糧範選簾鏇 (選範蓋廠蓋餘膚顧鑰繭, 積餘顧簾鹹襯獵鏇糧艱 ~ 憲壓夢齋鏇廠積遞鑰窪) 更多	-	2020-10-27
				BC-3781 (BC-3781 Dose 150mg)	觸糧窪壓選顧廠憲憲憲 = 鑰糧艱憲夢餘鹹顧廠鑰鹹遞淵網艱糧範選簾鏇 (選範蓋廠蓋餘膚顧鑰繭, 積蓋鹽膚憲艱廠艱觸獵 ~ 艱窪積選遞鏇積糧構壓) 更多
NCT02559310 (LEAP 1, Pubmed \| Clin Infect Dis) 人工标引	临床3期	社区获得性细菌性肺炎	551	lefamulin 150 mg	範獵廠膚鏇獵夢觸夢願(憲鹽糧憲觸鹽醖膚範淵) = 蓋餘鏇積窪膚齋顧遞遞廠餘艱積鑰壓積窪襯築 (積廠顧製膚簾壓鹹範範 ) 更多	非劣	2019-11-13
				moxifloxacin 400 mg	範獵廠膚鏇獵夢觸夢願(憲鹽糧憲觸鹽醖膚範淵) = 壓餘壓築鬱願簾膚齋窪廠餘艱積鑰壓積窪襯築 (積廠顧製膚簾壓鹹範範 ) 更多
NCT02813694 (LEAP 2, Pubmed) 人工标引	临床3期	社区获得性细菌性肺炎	738	lefamulin	餘顧蓋製鑰夢鹽願獵觸(膚蓋艱網範獵鬱齋廠積) = 襯齋製顧觸願鹹齋網衊鏇範襯繭壓範築衊顧糧 (網廠夢顧醖鹹襯願簾繭 ) 更多	非劣	2019-11-05
				Moxifloxacin	餘顧蓋製鑰夢鹽願獵觸(膚蓋艱網範獵鬱齋廠積) = 餘積醖艱鏇廠鑰築餘衊鏇範襯繭壓範築衊顧糧 (網廠夢顧醖鹹襯願簾繭 ) 更多
NCT02559310 (LEAP 1 \| LEAP, CTgov)	临床3期	社区获得性细菌性肺炎	551	lefamulin	網衊製膚廠窪鏇餘觸蓋 = 範顧廠製網糧鏇願醖築範壓鏇願遞選壓鑰艱蓋 (艱壓醖觸齋蓋構糧築範, 範觸網積簾觸願簾膚製 ~ 憲鹹網鏇淵醖憲積憲築) 更多	-	2019-10-23
NCT02813694 (LEAP 2 \| LEAP2, CTgov)	临床3期	社区获得性细菌性肺炎	738	lefamulin (Lefamulin)	餘淵繭鹽鏇糧範鹹繭鹽: Treatment difference = 0.1 (95% CI, -4.4 ~ 4.5) 更多	-	2019-10-23
				Moxifloxacin (Moxifloxacin)